References
- Gaidano G, Dalla F. Lymphomas. Cancer: Principles & Practice of Oncology, Fifth Edition, V. T. De Vita, S. H.S.A. Hellmann. Rosenberg. Lippincott-Raven Publishers, Philadelphia 1997; 261–297
- Cabanillas F, Hagemeister F, Bodey G, et al. IMVP-16: An effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy. Blood 1982; 3: 693–697
- Cabanillas F, Hagemeister F, McLaughlin P, et al. Results of MIME salvage regimen for recurrent or refractory lymphoma. J Clin Oncol 1987; 5: 407–12
- Ho A D, Del Valle F, Ruckle H, et al. Mitoxantrone and high-dose cytarabine as salvage therapy for refractory non-Hodgkin's lymphoma. Cancer 1989; 64: 1388–92
- Hopfinger G, Heinz R, Roller E, Schneider B, et al. Ifosfamide, mitoxantrone and etoposide (VIM) as salvage therapy of low toxicity in non-Hodgkin's lymphoma. Eur J Haematol 1995; 55: 223–227
- Zinzani P L, Barbieri E, Visani G, et al. Ifosfamide, epirubicin and etoposide (IEV) therapy in relapsed and refractory high-grade non-Hodgkin's lymphoma and Hodgkin's disease. Haematologica 1994; 79: 508–512
- Goss P, Shepherd F, Scott J G, et al. DICE (dexamethasone, ifosfamide, cisplatin, etoposide) as salvage therapy in non-Hodgkin's lymphomas. Leuk Lymphoma 1995; 18: 123–129
- Bosly A, Coiffier B, Gisselbrecht C, et al. Bone marrow transplantation prolongs survival after relapse in aggres-sive-Lymphoma patients treated with the LNH-84 regimen. J Clin Oncol 1992; 10: 1615A
- Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive NHL. N Engl J Med 1995; 333: 1540–1545
- Wilson W H, Bryant G, Bates S., et al. EPOCH Chemotherapy: Toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. J Clin Oncol 1993; 11: 1573–1582
- Velasquez W S, Swan F, Redman J. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 1988; 71: 117–122
- Sparano J A, Wiernik P H, Leaf A, Dutcher J P. Infusional cyclophosphamide, doxorubicin, and etoposide in relapsed and resistant non-Hodgkin's lymphoma: evidence for a schedule-dependent effect favoring infusional administration of chemotherapy. J Clin Oncol 1993; 11: 1071–1079
- Dufour P, Mors R, Lamy T, et al. Idarubicin and high-dose Ara-C: A new promising salvage treatment in relapsed or refractory NHL. Leuk Lymphoma 1995; 18: 179–184
- Engert A., Schnell R, Kiipper F, et al. A phase-II study with idarubicin, ifosfamide and VP-16 (IIVP-16) in patients with refractory or relapsed high-grade non-Hodgkin's lymphoma. Leuk Lymphoma 1997; 24: 513–522
- Villani F, Galimberti M, Comazzi R, et al. Evaluation of cardiac toxicity of idarubicin (4-Demethyldaunorubicin). Eur J Cancer Clin Oncol 1989; 25: 13–18
- Martoni A, Piana E, Guaraldi M, et al. Comparative phase II study of idarubicin versus doxorubicin in advanced breast cancer. Oncology 1990; 47: 427–432
- Dufour P, Mors R, Berthaud P, et al. Idarubicin and high dose cytarabine: a new salvage treatment for refractory or relapsing non-Hodgkin's lymphoma. Leuk Lymphoma 1996; 22: 329–334
- Lopez M, Di Lauro L, Papaldo P. Oral idarubicin in non-Hodgkin's lymphomas. Invest New Drugs 1986; 4: 263–267
- World Health Organisation. Handbook for reporting results of cancer treatment. WHO Offset Publication No.48, Geneva 1979; 5–42
- Niitsu N, Umeda M. Salvage chemotherapy for relapsed or refractory non-Hodgkin's lymphoma with a combination of ACES (high-dose Ara C, carboplatin, etoposide and steroids) therapy. Eur J Haematol 1996; 57: 320–4
- Case D C, Gerber M C, Gams R A, et al. Phase-II study of intravenous idarubicin in unfavorable NHL. Cancer Res 1992; 52: 3871–74
- Lokich J J, Moore C L, Anderson N R. Comparison of costs for infusion versus bolus chemotherapy administration: analysis of five standard chemotherapy regimens in three common tumors - Part one. Model projections for cost based on charges. Cancer 1996; 78: 294–299
- Gianni A M, Bregni M, Siena S, et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. NEJ Med 1997; 18: 290–297
- Goss P E. Non-Hodgkin's lymphomas in elderly patients. Leuk Lymphoma 1993; 10: 147–156
- Coiffier B. What treatment for elderly pts with aggressive lymphoma? [editorial]. Ann Oncol 1994; 5: 873–875